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Abstract
A 46 year old woman presented with a one month history of rash and mylagia. The history, clinical
findings and blood tests all supported a diagnosis of dermatomyositis. The patient later developed
dysphagia and was successfully treated with intravenous immunoglobulin. Investigations and
treatment of dysphagia in the context of dermatomyositis are discussed.
Background
Dermatomyositis commomly presents with fatigue, prox-
imal weakness, muscle tenderness and a characteristic
rash. It can occur in conjunction with an underlying
malignancy. Dysphagia can also occur and is associated
with a 31% one year mortality [1]. The authors present a
case of dermatomyositis in a 46 year old woman who
developed dysphagia and was successfully treated with
intravenous immunoglobulin.
Case report
A 46 year old caucasian female presented with a one
month history of a rash on the face and hands. She had
also noticed generalised myalgia. There was no history of
dysphagia, weight loss or night sweats. There had been no
recent foreign travel. A past medical history of pernicious
anaemia, treated with hydroxycobalamin injections, was
noted. No other regular medications were being taken or
had been started in the last month. Cardio-respiratory and
abdominal examination was unremarkable. Power in all
four limbs was graded MRC 5/5. A helitropic rash affect-
ing both upper eyelids and a scaly violaceous eruption on
the knuckles was noted. The full blood count, renal func-
tion and coagulation studies were normal. Serum B12 and
folate levels were also normal. Serum creatine kinase (CK)
was 9831 U/L (NR 20–180) and ESR was 54 mm/h (NR
0–20).
The history, clinical findings and blood tests all supported
a diagnosis of dermatomyositis and therefore high dose
prednisolone (60 mg OD) and methotrexate 10 mg per
week with folic acid supplementation was commenced.
The patient underwent a deltoid muscle biopsy which
demonstrated patchy atrophy of fibres and inflammation
around the fasicles compatible with dermatomyositis.
Computed tomography of the abdomen, chest and pelvis
was normal. Breast mammography revealed a normal
parenchymal pattern with no features supportive of
malignancy. Auto-antibodies including ANA and anti Jo 1
were negative. The patient was discharged 12 days later
with significant improvement in symptoms. The CK con-
tinued to normalise 1888 U/L.
The patient was readmitted 21 days later with worsening
dysphagia. Upper gastro-intestinal endoscopy demon-
strated poor primary contractions with swallowing. Fibro-
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optic endoscopic evaluation of swallowing highlighted
velo-pharyngeal dysfunction, inadequate clearance of
bolus from the pharynx and evidence of residue in the val-
leculae and piriform fossa. Oesophageal and gastric tran-
sit studies confirmed oesophageal dysmotility affecting
the medial and lower third of the oesophagus and mild
gastric stasis. The prednisolone was increased to 60 mg.
Given the findings of oesophageal and gastric delay, Intra-
venous immunoglobulin (IV IG) 40 g OD for three days
was given, with a significant improvement in symptoms.
Further IV IG was deemed unnecessary due to a paucity of
symptoms. The patient was continued on prednisolone
60 mg for a further four weeks before being reduced and
the methotrexate was increased to 15 mg per week. The
patient continued to be followed up by both the gastroen-
terologists and rheumatologists. One year after her initial
presentation, the patient described no dysphagia. Repeat
fibro-optic endoscopy and oesophageal transit studies
were not repeated given the resolution of symptoms.
Discussion
The idiopathic inflammatory myopathies are divided into
four subgroups: dermatomyositis (DM), polymyositis
(PM), inclusion body myositis (IBM) and an overlap syn-
drome with mixed characteristics [2]. DM is a comple-
ment mediated microangiopathy affecting the skin and
muscles [3]. Endocapillary deposition of the complement
C5b-9 membraneolytic attack complex leads to the loss of
capillaries, ischaemia and necrosis of muscle fibres [4].
The characteristic sign associated with DM is a heliotrope
(blue-purple) rash of the upper eyelids. A flat, red rash on
the face (often associated with periorbital oedema) and
upper trunk is also often noted. In the hands, Gottron's
papules (raised violaceous scaly eruption on the knuck-
les) and periungal erythema may be found. DM is associ-
ated with an occult malignancy in 20–30% of cases
especially colorectal, bladder, lung, non-Hodgkin's lym-
phoma, ovarian, pancreatic and stomach cancers. The risk
for developing a cancer remains for up to five years [5]. A
poorer prognosis is associated with old age, non-white
race, occurrence with an underlying malignancy, bulbar
involvement, cardio-respiratory involvement and delayed
treatment [6].
An incidence of 5–10 cases per 100,000 individuals has
been reported, affecting women more commonly with a
ratio of 2:1. Adults and children are equally affected, with
the peak incidence between the ages of 45 and 64 in
adults. Clinical features include fatigue, proximal muscle
weakness and muscle tenderness. Dysphonia, dysphagia
and breathlessness can all occur if the respective muscle
groups are affected. Extra-muscular manifestations
include fever, Raynaud's phenomenon, subcutaneous cal-
cifications and arthralgia. Subcutaneous calcifications are
rare in adults [5]. The characteristic rash, previously
described, can occur over the shoulders, upper arm and
back resulting in the termed "shawl sign". Investigations
should include full blood count, urea and electrolytes,
liver function tests (transaminases may be raised), creat-
ine kinase (CK) and a chest radiograph. An ECG, echocar-
diogram and pulmonary function tests should be
performed if cardio-respiratory involvement is suspected.
Anti-nuclear antibodies (ANA) are positive in 80% of
patients, whilst anti Jo-1 antibodies are positive in
approximately 20% [5]. CK levels are used to monitor dis-
ease activity but levels may have poor correlation with
clinical disability [6]. It is imperative that patients are
screened for an occult malignancy with investigations that
include computed tomography of the abdomen, chest
and pelvis, mammography and serum tumour markers.
MRI has been used to successfully to identify myositis of
affected muscle groups, as muscle oedema correlates well
with inflammatory changes. A muscle biopsy is still
required to make the diagnosis. Classical findings include
endomysial inflammation predominant in the perivascu-
lar regions or in the interfascicular septae, and around the
fascicles [3].
Principal treatment for DM is corticosteroids. Steroid
resistant disease is not uncommon, and methotrexate,
azathioprine, cyclosporine and cyclophosphamide have
all been used successfully. However a Cochrane Review
2005 [7] demonstrated a lack of high quality randomised
controlled trials that have assessed the efficacy and toxic-
ity of immunosuppression in the inflammatory myopa-
thies. Intravenous Immunoglobulin (IV IG) has been used
in patients refractory to steroid sparing treatment. The
mechanisms of action are not clear but it is known to
block the Fc receptors on the vascular wall [4] thus pre-
venting the membrane attack complex deposits from
entering endomysial capillaries. IV IG has been to shown
to have positive effect on myopathy [3] and on cutaneous
ulceration [8]. The dose recommended in the literature is
2 g/kg, to be repeated in six weeks depending upon clini-
cal response. Side effects are mild and include nausea and
headaches.
Dysphagia occurs in 10–73% of patients with an inflam-
matory myopathy [9]. The skeletal muscle activated-
oropharyngeal phase of swallowing is clearly affected
leading to the increased incidence of aspiration pneumo-
nia [2]. Horowitz et al [10] showed a high incidence of
gastric and oesophageal motor dysfunction particularly in
DM and PM, therefore suggesting that smooth muscle is
also affected. This leads to ineffective peristalsis and clini-
cal manifestation with gastro-oesophageal reflux, gas-
troparesis and constipation due to colonic inertia [11]. A
multi-disciplinary approach is essential, with the roles of
dieticians and speech and language therapists being
imperative. Assessment with video-fluoroscopic studiesPublish with BioMed Central    and   every 
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can help identify pharyngeal pooling, impaired tongue
base retraction, decreased laryngeal elevation and
cricopharyngeal dysfunction. Oesophageal and gastric
radionuclide transit studies are a safe, simple, non inva-
sive method of highlighting oesophageal and gastric
delay. Treatment options include botulinum injection,
cricopharyneal dilatation and myotomy. Swallowing
compensation techniques also have an important role to
play. PEG tube insertion may be required if swallowing
remains unsafe but the highest mortality has been
described in these patients [2]. Conventional immuno-
suppressive treatment is recommended but the treatment
of choice is IV IG [12].
Conclusion
Dysphagia commonly occurs in DM and can occur due to
oropharyngeal skeletal muscle or distal oesophageal and
gastric smooth muscle involvement. Malignancy needs to
be excluded. Investigations should include OGD, video
fluoroscopy and oesophageal and gastric transit studies.
The treatment of choice is IV IG.
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